ACM
AZN icon

Advent Capital Management’s AstraZeneca AZN Stock Holding History

Advent Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-45
Closed -$4K – 253
2018
Q3 		$4K Buy
+45
New +$3.4K ﹤0.01% 283

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Advent Capital Management's AZN Position: Q4 2018 in Review

Advent Capital Management sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 45 shares — an estimated $4K sold.

Advent Capital Management first reported a position in AZN in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 556 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

  • Advent Capital Management reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
  • Advent Capital Management sold 45 AstraZeneca shares in Q4 2018, an estimated $4K.
  • Advent Capital Management first reported a position in AstraZeneca in Q3 2018 and held it in 1 quarter.
  • Advent Capital Management's AstraZeneca position peaked at $4K in Q3 2018.
  • 556 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on Advent Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.